Pasithea Therapeutics (KTTA) Research & Development (2022 - 2026)

Pasithea Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Research & Development rose 70.09% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $9.2 million (up 28.06% YoY), while the FY2025 annual figure was $8.0 million, up 10.87% from the prior year.
• Research & Development came in at $2.9 million for Q1 2026 at Pasithea Therapeutics, up from $2.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $3.4 million in Q4 2023 to a low of $1.1 million in Q1 2023.
• A 5-year average of $2.0 million and a median of $1.7 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 141.73% in 2023 and tumbled 54.95% in 2024, its largest moves.
• Pasithea Therapeutics' Research & Development stood at $1.4 million in 2022, then jumped by 141.73% to $3.4 million in 2023, then sank by 54.95% to $1.5 million in 2024, then surged by 81.77% to $2.7 million in 2025, then grew by 7.2% to $2.9 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.9 million, $2.7 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison